About This Item
Código UNSPSC:
41116105
NACRES:
NA.22
Produtos recomendados
forma
solid (powder or film on well wall)
Nível de qualidade
adequação da reação
reagent type: ligand
concentração
125 μg/well
adequação
suitable for H-NMR
suitable for LC-MS
temperatura de armazenamento
2-8°C
Aplicação
The ComInnex IAP Ligand Library is an 80-member collection of in-silico-derived ligands targeting cellular inhibitor of apoptosis protein 1 (cIAP1). cIAP1 is an E3 ligase of interest for the development of protein degraders, specifically called specific and non-genetic IAP-dependent protein erasers (SNIPERs).
Based on the SAR rules outlined in IAP antagonist research, the binding tetrapeptide anchor of the natural SMAC inhibitor protein of IAPs (AVPI and AVPF) was used in identification of novel derivatives designed by 3D similarity.
The initial library was filtered via in silico IFD methods by docking to the BIR3 domain of the IAP crystal structures. The highest binding derivatives were selected and collected in a screening library, including the natural binding tetrapeptides and known MV1 reference compounds. IAP in silico leads are an optimal collection to begin IAP lead discovery at the bench for eventual development into bifunctional protein degraders. With the proper assay setup to measure protein degradation or protein-protein interactions (PPIs), the ComInnex IAP Ligand Library can also be a platform for molecular glue discovery.
Learn more about this library: Accelerating IAP Lead Discovery for Targeted Protein Degradation
To view a complete list of compounds in the library, including sdf, visit the CIX001 Plate Map.
To streamline the assessment of these in silico leads for target-specific bifunctional degraders, three IAP ligands with the highest docking scores were also prepared as degrader building blocks for simple attachment of a target warhead.
Based on the SAR rules outlined in IAP antagonist research, the binding tetrapeptide anchor of the natural SMAC inhibitor protein of IAPs (AVPI and AVPF) was used in identification of novel derivatives designed by 3D similarity.
The initial library was filtered via in silico IFD methods by docking to the BIR3 domain of the IAP crystal structures. The highest binding derivatives were selected and collected in a screening library, including the natural binding tetrapeptides and known MV1 reference compounds. IAP in silico leads are an optimal collection to begin IAP lead discovery at the bench for eventual development into bifunctional protein degraders. With the proper assay setup to measure protein degradation or protein-protein interactions (PPIs), the ComInnex IAP Ligand Library can also be a platform for molecular glue discovery.
Learn more about this library: Accelerating IAP Lead Discovery for Targeted Protein Degradation
To view a complete list of compounds in the library, including sdf, visit the CIX001 Plate Map.
To streamline the assessment of these in silico leads for target-specific bifunctional degraders, three IAP ligands with the highest docking scores were also prepared as degrader building blocks for simple attachment of a target warhead.
Ações bioquímicas/fisiológicas
80 compounds are arranged in 96-microtube format with two open rows for screening controls if using liquid handling setups. One compound per tube (125 μg in solid form). Compound concentration in assays will vary depending on assay type, but common screening library stock solutions are 2 mM or 10 mM in DMSO.
produto relacionado
Nº do produto
Descrição
Preços
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 3
Escolha uma das versões mais recentes:
Certificados de análise (COA)
Lot/Batch Number
Lamentamos, não temos COA para este produto disponíveis online no momento.
Se precisar de ajuda, entre em contato Atendimento ao cliente
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Norihito Shibata et al.
Cancer science, 108(8), 1657-1666 (2017-05-31)
Chromosomal translocation occurs in some cancer cells, which results in the expression of aberrant oncogenic fusion proteins that include BCR-ABL in chronic myelogenous leukemia (CML). Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica